Arcus Biosciences (RCUS) to Post Quarterly Earnings on Wednesday

Arcus Biosciences (NYSE:RCUS) is projected to release its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Arcus Biosciences to post earnings of ($0.8912) per share and revenue of $22.2150 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.10). Arcus Biosciences had a negative return on equity of 68.97% and a negative net margin of 156.36%.The firm had revenue of $17.00 million for the quarter, compared to analyst estimates of $29.48 million. During the same quarter last year, the company earned ($1.14) earnings per share. The firm’s revenue for the quarter was down 39.3% on a year-over-year basis. On average, analysts expect Arcus Biosciences to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Arcus Biosciences Stock Down 2.6%

NYSE:RCUS opened at $27.11 on Wednesday. Arcus Biosciences has a 52 week low of $8.84 and a 52 week high of $31.74. The stock’s fifty day moving average is $26.76 and its two-hundred day moving average is $23.93. The stock has a market capitalization of $3.41 billion, a price-to-earnings ratio of -8.53 and a beta of 0.80. The company has a quick ratio of 4.04, a current ratio of 4.04 and a debt-to-equity ratio of 0.19.

Insider Activity at Arcus Biosciences

In related news, CFO Robert C. Goeltz II sold 7,763 shares of Arcus Biosciences stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $25.63, for a total value of $198,965.69. Following the completion of the transaction, the chief financial officer owned 84,161 shares in the company, valued at $2,157,046.43. The trade was a 8.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Juan C. Jaen sold 20,067 shares of the business’s stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $28.62, for a total transaction of $574,317.54. Following the transaction, the president owned 822,240 shares of the company’s stock, valued at $23,532,508.80. This trade represents a 2.38% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 110,325 shares of company stock valued at $3,174,319 over the last 90 days. 7.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Arcus Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of RCUS. Suvretta Capital Management LLC increased its holdings in Arcus Biosciences by 40.7% in the fourth quarter. Suvretta Capital Management LLC now owns 5,188,858 shares of the company’s stock valued at $123,650,000 after buying an additional 1,500,000 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Arcus Biosciences by 309.4% during the 4th quarter. Wellington Management Group LLP now owns 5,184,509 shares of the company’s stock worth $123,547,000 after buying an additional 3,918,220 shares during the last quarter. State Street Corp boosted its position in shares of Arcus Biosciences by 34.8% during the 4th quarter. State Street Corp now owns 4,576,969 shares of the company’s stock worth $109,069,000 after acquiring an additional 1,182,115 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Arcus Biosciences during the 4th quarter worth about $80,731,000. Finally, Siren L.L.C. increased its holdings in shares of Arcus Biosciences by 3.3% in the 4th quarter. Siren L.L.C. now owns 3,007,077 shares of the company’s stock valued at $71,659,000 after acquiring an additional 95,000 shares during the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on RCUS. Wedbush boosted their price objective on Arcus Biosciences from $37.00 to $41.00 and gave the company an “outperform” rating in a report on Thursday, April 2nd. Truist Financial started coverage on Arcus Biosciences in a report on Monday, May 18th. They set a “buy” rating and a $35.00 target price for the company. Wall Street Zen downgraded Arcus Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. The Goldman Sachs Group lifted their target price on Arcus Biosciences from $30.00 to $34.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Finally, HC Wainwright boosted their price target on shares of Arcus Biosciences from $32.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, July 20th. Eight equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.40.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.